Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire Sells Shares Worth $30,718.73

On December 16th, Terrance Mcguire, a director at Invivyd, Inc. (NASDAQ:IVVD), made the decision to sell 65,359 shares of the company’s stock. The shares were sold at an average price of $0.47, resulting in a total transaction value of $30,718.73. Following this sale, Mcguire now possesses a total of 4,012,320 shares in Invivyd, with a current value of around $1,885,790.40. This sale represents a 1.60% reduction in his stake in the company. The details of this transaction were reported in a filing with the Securities and Exchange Commission.

In addition to this recent sale, Terrance Mcguire has been active in trading Invivyd’s stocks. On December 11th, he sold 160,400 shares at an average price of $0.59, totaling $94,636.00. Furthermore, on December 9th, he sold another 150,000 shares at an average price of $0.61, amounting to $91,500.00.

Current Stock Performance

As of December 16th, the stock of Invivyd is trading at $0.45, which is down by 17.6%. The trading volume for the day was 1,228,420 shares, significantly higher than its average volume of 651,886. Invivyd's fifty-day moving average stands at $0.82, while the two-hundred-day moving average is $1.05. The company's market capitalization amounts to approximately $53.89 million, with a price-to-earnings ratio of -0.23. Over the past year, Invivyd’s stock has experienced a low of $0.45 and a high of $5.20.

Analyst Insights

Several research firms have recently revised their price targets for Invivyd shares. Notably, Morgan Stanley has decreased its target price from $9.50 to $3.55 while maintaining an “overweight” rating. HC Wainwright has revised its price objective for Invivyd from $15.00 to $10.00 with a “buy” rating. Additionally, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating. D. Boral Capital also reaffirmed a “buy” rating with a target price of $9.00. Overall, four analysts classify Invivyd with a buy rating, while one gives it a strong buy, leading to a consensus rating of “Buy” and an average price target of $7.89 according to MarketBeat.com.

Institutional Holdings

Recent changes have also occurred regarding institutional investments in Invivyd. State Street Corp has increased its holdings in the company by 3.7% during the third quarter, now owning 1,018,640 shares valued at $1,039,000 after purchasing an additional 35,904 shares. Similarly, Marshall Wace LLP has raised its position by 4.2%, now possessing 786,899 shares valued at $866,000 after the last quarter's transactions. Acadian Asset Management LLC significantly grew its stake by 232%, currently holding 678,706 shares valued at $745,000 after adding 474,301 shares. Other institutional investors such as Duquesne Family Office LLC and Renaissance Technologies LLC have also acquired new positions in Invivyd. Overall, institutional investors and hedge funds own approximately 70.36% of the company’s stock.

About Invivyd, Inc.

Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions aimed at treating infectious diseases. The company has developed a platform known as INVYMAB, which integrates viral surveillance and predictive modeling using advanced methods in antibody engineering.

Invivyd, Stocks, Sale